Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 with or without Chemotherapy in Unresectable Stage III NSCLC
NCT04580498Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Nov 2020
- Primary completion
- Jul 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04580498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580498.